5 11, 2019

Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

2019-12-10T12:04:11+01:00November 5th, 2019|biomarker, biomarkers, drug development, drug discovery, LMD, microRNAs, Personalized medicine, safety, Vivomicx|0 Comments

We want to draw your attention to the latest publication with our partner Vivomicx. Together we have developed a combination of laser microdissection (LMD) and high quality qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. Our new approch allows to: Discover differential expression patterns between “healthy” and “diseased” tissues on the cellular level; [...]

24 10, 2019

meet TAmiRNA 2019

2019-12-09T09:21:53+01:00October 24th, 2019|biomarker, biomarkers, microRNAs, Personalized medicine|0 Comments

2019 TAmiRNA showcases at several conferences 63rd Annual Meeting of the Society of Thrombosis and Haemostasis Research, 27 February-2 March 2019, Berlin, Germany 9th international Gene Quantification Event, 18-22 March, Freising-Weihenstephan, Germany ECTS (European Calcified Tissue Society) 2019, 11-14 May 2019, Budapest, Hungary The 9th International Conference on Children’s Bone Health, 22-25 June 2019, Salzburg, Austria British Orthopaedic Society, 4-6 September 2019, Cardiff, UK ASBMR 2019 Annual Meeting, 20-23 September 2019, Orlando, Florida Safety Pharmacology Society Annual Meeting, 23-26 September 2019, Barcelona, Spain Knochen, Muskeln und Gelenke - Update 2019 "Neues aus der Forschung und Klinik", 8-9 November 2019, Berlin, Germany BIO-Europe, 11-13 November 2019, Hamburg, Germany RNA Targeting conference, 26-27 November 2019, Frankfurt. Germany

18 09, 2019

TAmiRNA GmbH is part of the EU-funded Innovative Training Network FIDELIO

2019-12-09T09:21:39+01:00September 18th, 2019|biomarkers, bone diseases, diabetes, microRNAs, Personalized medicine|0 Comments

Diabetes mellitus is a widespread metabolic disease, with negative/adverse effects on many organ systems. Diabetes also significantly affects bone health. An increased risk of bone fractures and impaired fracture healing has been observed in patients, but the mechanisms are not fully understood. In order to investigate the links between diabetes and the bone system, the EU project "FIDELIO" will run for four years starting October 2019. This European Training Network, coordinated by scientists from the Faculty of Medicine of the Technical University of Dresden, is funded by the EU Marie Skłodowska-Curie Actions program with a total of 3.8 million €. FIDELIO aims to train the next generation of scientists in order to tackle the challenges of diabetic [...]

26 06, 2019

University Medical Center Groningen (UMCG) , TAmiRNA GmbH & Vivomicx BV announce their collaboration to unmask the molecular signature of sepsis induced multi organ failure.

2019-12-09T09:21:23+01:00June 26th, 2019|biomarkers, LMD, microRNAs, safety, Vivomicx|0 Comments

UMCG, TAmiRNA, and Vivomicx today announced their collaboration to unmask the molecular signature of sepsis induced multi organ failure and shed light on diagnosis and therapeutic options. Sepsis is the body’s response to infection. Sepsis kills and disables millions of patients worldwide. The role of the microvasculature in all organs has been identified as central, yet understudied in the pathophysiology leading to Multi Organ Failure (MOF) in critically ill patients with sepsis. This translational project combines cutting edge molecular research at the level of kinome, gene expression, and microRNome in samples of patients who suffered from sepsis and of animal models of this disease. In both human and mouse lungs and kidneys we will enrich the samples [...]

30 04, 2019

TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

2019-12-09T09:20:21+01:00April 30th, 2019|biomarkers, drug development, drug discovery, exosomes, liquid biopsies, microRNAs, Personalized medicine, safety|0 Comments

Early and reliable detection and monitoring of adverse events is essential for improving of patient safety, reducing late attrition of drug candidates, and enhancing understanding of toxic mechanisms. The Translational Safety Biomarker Pipeline (TransBioLine) project will focus on development of biomarkers of injury for liver, kidney, pancreas, vasculature, central nervous system (CNS) and the development of non-invasive microRNA biomarkers using liquid biopsies. The project is coordinated by the University of Zurich with Pfizer as industry lead, and involves 27 partners (pharmaceutical companies, small and medium-sized enterprises, and academic institutions) from ten European countries and the United States of America. With a total budget of € 28 million, the EU and the pharmaceutical companies involved are financing the [...]

30 04, 2019

TAmiRNA and advanceCOR receive Eurostars project “thrombomiR”

2019-12-09T09:21:00+01:00April 30th, 2019|biomarkers, drug development, drug discovery, microRNAs, Personalized medicine, safety, thrombomiR|0 Comments

TAmiRNA and advanceCOR, a drug developing biotechnology company which focuses on personalized medicine in cardiovascular diseases, receive Eurostars project entitled: ”A novel microRNA-based platelet function biomarker for personalized anti-thrombotic treatment”.  The aim of the Eurostars project is to validate the use of the thrombomiR™ kit for management of anti-thrombotic therapies. The thrombomiR™ kit is a minimally invasive blood test that can determine changes in platelets reactivity (for example due to a therapy), based on the quantitative analysis of microRNAs, Specifically, the thrombomiR™ kit allows the targeted detection and quantitation of platelet-specific microRNAs in blood plasma. The concentration of these microRNAs increases in the course of activation of platelets and decreases as a result of therapeutic inactivation. Thus, [...]

30 01, 2019

Ask the Expert: kit or service, NGS or qPCR – what is the best choice for my microRNA biomarker project?

2019-12-09T09:19:33+01:00January 30th, 2019|biomarkers, exosomes, liquid biopsies, LMD, microRNA services, microRNAs, osteomiR, thrombomiR|0 Comments

Can't find the answer to your question on our site? Not sure which method is right for your research? Get in touch with our experts at TAmiRNA - they will answer your questions and help to move from your ideas to results. Get in touch

16 07, 2018

TAmiRNA receives FFG EARLY STAGE for the development of novel theranostic solutions based on microRNA biomarkers – the PATH project.

2019-12-09T09:18:35+01:00July 16th, 2018|biomarkers, exosomes, liquid biopsies, microRNAs|0 Comments

PATH stands for "Project for Advancing the Application of MicroRNAs as THeranostic Biomarkers". The aim of this project is to create optimal framework conditions for successful research and development of the application of microRNAs as theranostic biomarkers. “Theranostics” means the increasingly close integration of diagnostics and therapy. The aim of theranostics is to enable the right therapy for the right patient at the right time. A biomarker generally refers to a measurable indicator of a biological state or condition. MicroRNAs are a new class of biomarkers with enormous potential for applications in theranostics. They are short regulatory RNA molecules that are essential for the proper function of cells and tissues. The development of diseases is mostly due [...]